for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Mercados

FACTBOX-Development of AstraZeneca's potential coronavirus vaccine

    * For FACTBOX on vaccines and treatments, click:


 (Updates with trials being paused)
    Sept 9 (Reuters) - AstraZeneca has paused global
trials of its potential COIVD-19 vaccine after an unexplained
illness in a participant, a move seen as dimming prospects
for an early rollout.
    The British drugmaker said this was "routine action" in
such scenarios.
    Although drugmakers are racing to combat the pandemic
which has killed more than 895,000 people and infected nearly
28 million, safety of a prospective vaccine comes "first and
foremost", the World Health Organization's chief scientist
said.
    AstraZeneca's vaccine is widely seen as one of the
leading candidates, with reports the United States is aiming
for a fast-track approval before the November presidential
election.
    AstraZeneca has been granted protection from future
liability claims related to the vaccine by most of the
countries with which it has struck supply agreements, a
senior executive told Reuters.
    Below are the main details of the vaccine and its supply
and production deals.
    
    TYPE
    * AZD1222 or ChAdOx1 nCoV-19 is a recombinant viral
vector
vaccine developed by the University of Oxford and licensed to
AstraZeneca in April.
    * It uses a weakened version of a chimpanzee common cold
virus
that encodes instructions for making proteins from the novel
coronavirus to build immunity.

    
    PROTECTION DURATION
    * The shot is likely to provide protection for about a
year,
and AstraZeneca is leaning towards a two-dose strategy.


    
    EXPECTED COST
    * AstraZeneca says it will be able to manufacture at a
few
dollars per dose.
    * Pricing in Latin America, while still not final, is not
expected to exceed $4 per dose.
    * Serum Institute said it will price the shot at $3 per
dose
for India and other emerging economies.
    * Italy's health ministry says an AZD1222 shot would cost
about
2.5 euros ($2.8) per dose in Europe.
    * AstraZeneca does not expect to profit from the vaccine
candidate during the pandemic.
    * Costs in other regions have not been disclosed.

    
    TRIALS
    * AstraZeneca paused global trials after an unexplained
illness
in a participant.
    * Britain's Health Secretary Matt Hancock said
AstraZeneca's
decision was a challenge but would not necessarily set back
efforts to develop a vaccine.
    * Britain's medical regulator is urgently reviewing
information
available to determine whether AstraZeneca can restart
trials.
    * Serum Institute of India said trials of AstraZeneca's
COVID-19 vaccine candidate in the country were ongoing and
have not faced any issues.
    * AstraZeneca has begun enrolling adults for a
U.S.-funded,
30,000-subject late-stage study of the vaccine. 
    * AstraZeneca's CEO said good data had come in on the
vaccine,
after early-stage trials showed it was safe and produced an
immune response. 
    * Trials at different stages were underway in Britain,
Brazil,
South Africa, United States and India. Trials were planned in
Japan and Russia as well.

    * Talks are ongoing with Mexico, and a smaller
early-stage
study was being conducted in South Africa to see how the
vaccine works in those with HIV. 

    
    TIMELINE    
    * There is uncertainty over when the vaccine could be
rolled
out after AstraZeneca paused global trials.
    * Data could be given to regulators this year.

    * The vaccine could be rolled out by year-end, the lead
developer said in July.
    * Data from late-stage studies is expected around
September.

    * Delivery of the first doses is expected between
September and
October.
    * Experts have predicted a safe and effective vaccine
could
take 12-18 months to develop.    

    
    TARGET DOSES
    * 3 billion.
    

    TIE-UPS 
    * Even before conclusive evidence of the vaccine's
success or
failure, AstraZeneca has signed deals to produce and supply
the shot. With U.S. backing, it also tied up with IQVIA
 in July to speed up trials. 

    
    MANUFACTURING DEALS  
    
    (Most recent first)     

    
 FIRM          BASED IN  DEAL VALUE   FOR            FURTHER
 Oxford        UK        15 million   Unknown doses  [nL4N2FY
 Biomedica               pounds       for            2E4]
                         upfront to   large-scale    
                         reserve      commercial     
                         manufacturi  manufacture    
                         ng           under          
                         capacity,    expanded deal  
                         further 35                  
                         million                     
                         pounds plus                 
                         costs                       
                         payable                     
                         until end                   
                         of 2021                     
 Catalent      U.S.      Undisclosed  Making the     [nL4N2DS
                                      drug           2XW]
                                      substance      
                                      used in the    
                                      vaccine at     
                                      its Maryland   
                                      facility.      
                                      AZ's second    
                                      deal with      
                                      firm           
 Foundation    Mexico    Unknown      Latin          [nL1N2FF
 of Mexican                           American       01U]
 billionaire                          supply with    
 Carlos Slim                          Argentina,     
                                      excluding      
                                      Brazil, could  
                                      reach 250      
                                      million        
 mAbxience of  Argentin  Unknown      Initially      [nL1N2FF
 the INSUD     a                      producing 150  01U]
 Group                                million doses  
                                      for Latin      
                                      America,       
                                      excluding      
                                      Brazil         
 Kangtai Bio   China     Unknown      Annual         [nL4N2F8
                                      production     2GT]
                                      capacity of    
                                      at least 100   
                                      million doses  
                                      this year,     
                                      and  at least  
                                      200 million    
                                      doses by the   
                                      end of next    
                                      year           
 Emergent      U.S.      $174         Undisclosed    [nL3N2EY
 BioSolutions            million      doses in       2LF]
                                      second deal    
                                      with AZ        
 SK            South     Unknown      Undiluted      [nL3N2ES
 Bioscience    Korea                  solutions of   288]
                                      the vaccine    
                                      until early    
                                      next year      
 R-Pharm       Russia    Unknown      Unknown doses  [nL5N2EO
                                                     2S4]
 Daiichi       Japan     Unknown      Unknown doses  [nL4N2E3
 Sankyo                                              19J]
                                                     
 Fundação      Brazil    $127         About 30       [nL1N2E4
 Osvaldo Cruz            million      million doses  03I]
 (Fiocruz)                                           
 Symbiosis     Scotland  Undisclosed  Clinical       [nL4N2E1
 Pharmaceutic                         trial supply   2U2]
 al                                                  
 Cobra         U.S.      Undisclosed  One million    [nL8N2DT
 Biosciences                          doses per      1YB]
                                      month          
 Catalent      U.S.      Undisclosed  Vial filling   [nL4N2DS
                                      and packaging  2XW]
                                      capacity at    
                                      its            
                                      manufacturing  
                                      facility in    
                                      Anagni, Italy  
 Emergent      U.S.      $87 million  300 million    [nL4N2DO
 BioSolutions                         doses          2U1]
                                                     
 Serum         India     Undisclosed  One billion    [nL4N2DH
 Institute of                         doses for low  3LY]
 India                                and            
                                      middle-income  
                                      countries,     
                                      with 400       
                                      million        
                                      before end of  
                                      2020           
 Oxford        UK        Undisclosed  Manufacturing  [nL4N2DL
 Biomedica                            unknown        1B3]
                                      number of      
                                      doses          
    
    
               
    SUPPLY DEALS
    
    (Most recent first)
    
    
 REGION/FIRM   DOSES     FUNDING      DELIVERIES     FURTHER
 Australia     "Enough"  Undisclosed  Unknown        [nL4N2FK
               for                                   44P]
               populati                              
               on of 25                              
               million,                              
               free of                               
               cost                                  
 European      300       336 million  By end of      [nL8N2FT
 Union         million,  euros as     2020           5QW]
               with      downpayment                 
               option    , overall                   
               of        price                       
               addition  undisclosed                 
               al 100                                
               million                               
 Latin         Initiall  Estimated    First half of  [nL1N2FF
 America,      y         at $600      2021           01U]
 excluding     produce   million for                 
 Brazil        150       the first                   
               million   150 million                 
               doses,    doses                       
               and                                   
               eventual                              
               ly make                               
               at least                              
               400                                   
               million                               
 Japan         120       Undisclosed  30 million     [nL4N2F9
               million                doses by       2XN]
               doses                  March 2021     
 China         Aims for  Unknown      By end of      [nL4N2F8
               annual                 2020           2GT]
               producti                              
               on                                    
               capacity                              
               of at                                 
               least                                 
               100                                   
               million                               
               doses                                 
               this                                  
               year,                                 
               and  at                               
               least                                 
               200                                   
               million                               
               doses by                              
               the end                               
               of next                               
               year                                  
 South Korea   Unknown   Unknown      Unknown        [nL3N2ES
                                                     288]
 Russia        Unknown   Unknown      Unknown        [nL5N2EO
                                                     2S4]
 Israel        Unknown   Unknown      Unknown        [nL5N2ER
                                                     4TW]
 Brazil        Initiall  1.9 billion  Unknown        [nL1N2F8
               y         reais                       2TN]
               receive   ($339                       
               100       million)                    
               million                               
               doses                                 
 France,       300       750 million  By end of      [nL8N2DQ
 Germany,      million,  euros for    2020           0GG]
 Italy and     with      300 million                 
 the           option    doses                       
 Netherlands   of                                    
 under         addition                              
 Inclusive     al 100                                
 Vaccines      million                               
 Alliance                                            
 (IVA)                                               
 Italy (part   75        185 million  By end of      [nL8N2DS
 of IVA)       million   euros        2020           2XO]
 Serum         One       Unknown      400 million    [nL4N2DH
 Institute of  billion,               before the     3LY]
 India         unspecif               end of 2020    
               ied                                   
               number                                
               of doses                              
               will go                               
               to India                              
 Epidemic      300       $750         Some before    [nFWN2DH
 response      million   million,     end of 2020    0DK]
 group CEPI              with $383                   
 and Vaccine             from CEPI                   
 alliance                                            
 GAVI                                                
 United        300       $1.2         By Oct         [nL4N2D3
 States        million   billion                     1M3]
 United        100       Unknown      By Sept/Oct    [nRSU597
 Kingdom       million                               2Na]
 

    
    (Sources: Reuters reporting, press releases)
    
    
    ($1 = 0.8850 euros)
    ($1 = 0.8156 pounds)
    ($1 = 5.6107 reais)
    

   

 (Reporting by Pushkala Aripaka in Bengaluru; Additional
reporting by Tanishaa Nadkar; Editing by Jan Harvey, Mark
Potter, Louise Heavens and Alexander Smith)
  
for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up